GILD

Business Context and Reporting Period

This Form 10-Q covers Gilead Sciences, Inc. for the three-month period ended March 31, 2000. Gilead is an independent biopharmaceutical company focused on infectious diseases and cancer. Key marketed products include AmBisome (antifungal), DaunoXome (Kaposi's Sarcoma), and VISTIDE (CMV retinitis). The company also holds a collaboration with Roche for Tamiflu (influenza). Financial results for the prior year period (March 31, 1999) have been restated to reflect the pooling of interests with NeXstar Pharmaceuticals, Inc., acquired in July 1999.

Key Financial Metrics

Revenue Breakdown: Product sales were $36.3 million (95% from AmBisome), Royalty revenue was $8.0 million (driven by Tamiflu), and Contract revenue was $0.8 million.

Material Changes vs. Prior Period

• Profitability Improvement: Net loss narrowed significantly from $15.5 million to $5.8 million, driven by higher revenues and reduced operating expenses.
• Revenue Growth: Total revenues increased 18% year-over-year. Royalty revenue surged 285% primarily due to $5.4 million in Tamiflu royalties recognized from Roche's Q4 1999 sales.
• Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased by $4.2 million ($21.8M to $17.6M). This was due to the absence of $1.5 million in merger-related expenses present in Q1 1999 and cost savings from integrating NeXstar.
• R&D Increase: Research and Development expenses rose slightly to $26.6 million from $25.6 million, reflecting increased spending on tenofovir (HIV) and adefovir (HBV) programs.
• Liquidity: Cash and marketable securities decreased by $2.6 million quarter-over-quarter due to operating cash usage and a $2.5 million investment in the unconsolidated affiliate Proligo.

Outlook, Risks, and Management Commentary

• Outlook: Management expects R&D expenses to continue increasing in 2000 due to late-stage development of HIV and HBV candidates. SG&A expenses are also expected to rise to support marketing and sales activities. The company believes current capital resources are adequate for the foreseeable future.
• Key Risks:
  • Product Concentration: Heavy reliance on AmBisome sales (95% of product revenue) exposes the company to competition from lower-priced alternatives.
  • Collaboration Dependence: Revenue depends on partners like Roche (Tamiflu) and Fujisawa (AmBisome US/Canada). Disputes or lack of partner resources could adversely affect results.
  • Currency Fluctuations: A significant portion of sales is in foreign currencies; a stronger U.S. Dollar could reduce reported revenues and margins.
  • Regulatory Uncertainty: FDA or foreign agency rejection of clinical trial results or manufacturing processes could halt commercialization.
• Contingencies: The company has $6.4 million in accounts receivable from Greece, Spain, and Italy that are more than 120 days past due, though management believes these are collectible. There is potential for up to $21.2 million in future milestone payments from Roche.

Investor Verification Checklist

• Verify the sustainability of AmBisome sales volumes given the 95% revenue concentration and competitive pricing pressures.
• Monitor the collection status of the $15.0 million in past-due receivables from Greece, Spain, and Italy.
• Assess the progress and regulatory status of the tenofovir (HIV) and adefovir (HBV) development programs driving R&D spend.
• Review the terms of the collaboration with Roche regarding Tamiflu royalties and potential future milestone payments.
• Track the impact of foreign currency exchange rates on gross margins, as manufacturing costs are in USD while sales are often in foreign currencies.